
Sign up to save your podcasts
Or


Returning a second time in the IC Interviews hot seat, Terry Smith is one of the biggest names in the investing world. Having set up the eponymous Fundsmith in 2010, he now manages more than £22bn of British savers’ money and has had his fair share of celebration and criticism.
Funds editor Dave Baxter and Smith unpack everything from Magnificent Seven stocks and the effect of weight-loss drugs on stock markets, to consumer staples and the reason Smith doesn’t want to own market favourite, Nvidia.
Also, find out what quality Smith looks for in companies and fund managers, plus why the fund’s allocation to UK stocks is so minimal.
Timestamps
00:38 Magnificent Seven stocks
3:52 Nvidia
6:41 AI
08:57 Consumer staples and weight-loss drugs
12:06 Novo Nordisk
17:36 What he looks for in companies
20:23 Nike
22:07 Asset allocation and share buybacks
24:48 UK companies and Asia
29:19 Financials
30:27 Judging when there’s a crisis versus a mispricing
35:09 Criticisms of the buy and sell process
39:44 Atlas Copco
41:44 Next and Autotrader
Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial
*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.
Investors' Chronicle is a service by the Financial Times.
Hosted on Acast. See acast.com/privacy for more information.
By Investors' Chronicle3.7
77 ratings
Returning a second time in the IC Interviews hot seat, Terry Smith is one of the biggest names in the investing world. Having set up the eponymous Fundsmith in 2010, he now manages more than £22bn of British savers’ money and has had his fair share of celebration and criticism.
Funds editor Dave Baxter and Smith unpack everything from Magnificent Seven stocks and the effect of weight-loss drugs on stock markets, to consumer staples and the reason Smith doesn’t want to own market favourite, Nvidia.
Also, find out what quality Smith looks for in companies and fund managers, plus why the fund’s allocation to UK stocks is so minimal.
Timestamps
00:38 Magnificent Seven stocks
3:52 Nvidia
6:41 AI
08:57 Consumer staples and weight-loss drugs
12:06 Novo Nordisk
17:36 What he looks for in companies
20:23 Nike
22:07 Asset allocation and share buybacks
24:48 UK companies and Asia
29:19 Financials
30:27 Judging when there’s a crisis versus a mispricing
35:09 Criticisms of the buy and sell process
39:44 Atlas Copco
41:44 Next and Autotrader
Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial
*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.
Investors' Chronicle is a service by the Financial Times.
Hosted on Acast. See acast.com/privacy for more information.

1,240 Listeners

50 Listeners

40 Listeners

86 Listeners

1,331 Listeners

584 Listeners

31 Listeners

95 Listeners

261 Listeners

49 Listeners

115 Listeners

18 Listeners

1,033 Listeners

845 Listeners

141 Listeners

1,023 Listeners

113 Listeners

13 Listeners

10 Listeners

4 Listeners

195 Listeners

54 Listeners

194 Listeners

10 Listeners

38 Listeners